SRTD biotech, a Jülich, Germany-based biotech startup, raised an undisclosed amount in Seed funding.
The round was led by High-Tech Gründerfonds alongside undisclosed business angels.
The company intends to use the funds to accelerate the development of novel RNA therapeutics.
Founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen, SRTD is a biotech startup aiming to develop highly efficient RNA-based liver cancer drugs based on proprietary platform technology. It aims to bring liver cancer drugs into clinical development within the next three years. The team consists of experts in molecular biology, cell biology, chemistry, translational sciences and business development.
FinSMEs
18/11/2024